Amphastar Pharmaceuticals (AMPH) Projected to Post Quarterly Earnings on Thursday

Amphastar Pharmaceuticals (NASDAQ:AMPH) will likely be posting its Q4 2025 results after the market closes on Thursday, February 26th. Analysts expect Amphastar Pharmaceuticals to post earnings of $0.97 per share and revenue of $190.48 million for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, February 26, 2026 at 5:00 PM ET.

Amphastar Pharmaceuticals Stock Up 0.4%

AMPH stock opened at $27.67 on Wednesday. Amphastar Pharmaceuticals has a 1-year low of $20.39 and a 1-year high of $32.56. The business’s 50 day simple moving average is $27.32 and its 200 day simple moving average is $27.06. The company has a current ratio of 3.12, a quick ratio of 2.21 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $1.27 billion, a PE ratio of 12.24, a PEG ratio of 5.03 and a beta of 0.88.

Analyst Ratings Changes

AMPH has been the topic of several research reports. Barclays began coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, December 9th. They issued an “equal weight” rating and a $30.00 price objective on the stock. Zacks Research downgraded shares of Amphastar Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, November 14th. Needham & Company LLC lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $34.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Amphastar Pharmaceuticals in a research report on Monday, December 29th. Two analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $31.00.

Insider Activity

In other news, Director Floyd F. Petersen sold 2,426 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were sold at an average price of $25.92, for a total transaction of $62,881.92. Following the transaction, the director directly owned 71,368 shares of the company’s stock, valued at approximately $1,849,858.56. This trade represents a 3.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Rong Zhou sold 9,787 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $26.20, for a total transaction of $256,419.40. Following the completion of the sale, the executive vice president owned 138,043 shares of the company’s stock, valued at approximately $3,616,726.60. The trade was a 6.62% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 13,950 shares of company stock valued at $363,925 in the last quarter. Corporate insiders own 27.10% of the company’s stock.

Institutional Investors Weigh In On Amphastar Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. Occudo Quantitative Strategies LP bought a new position in Amphastar Pharmaceuticals in the second quarter valued at about $362,000. PDT Partners LLC acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $336,000. Quantinno Capital Management LP acquired a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter valued at approximately $259,000. Franklin Resources Inc. bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $254,000. Finally, Commonwealth Equity Services LLC increased its position in Amphastar Pharmaceuticals by 11.2% during the 4th quarter. Commonwealth Equity Services LLC now owns 8,742 shares of the company’s stock worth $234,000 after purchasing an additional 882 shares in the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company’s manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.

Amphastar’s portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.